Cytodyn Inc (CYDY)

[ScienceOC]

Let's see...

Published treatments in peer reviewed journal (this month).

Including Remedesivir, to me, these are not effective treatments.

If data from leronlimab is good and Dr, P's paper gets published, then FDA has to take take action and support/fund leronlimab.

This will put leronlimab on top of treatment protocol.

1) Remedesivir vs placebo (DOI: 10.1056/NEJMoa2007764 - shortened hospital stay but no difference in mortality rate. 114/541 patients taking Remdesivir showed ADVERSE side effects.

2) Lopinavir and ritonavir (N Engl J Med 2020; 382:1787-1799
DOI: 10.1056/NEJMoa2001282)
"Conclusions: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care."

3)Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 (DOI: 10.1056/NEJMoa2012410
Conclusion: "In this observational study involving patients with Covid-19..., hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death."

4)Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State ( JAMA.May 11, 2020 doi:10.1001/jama .2020. 8630
Conclusion: "Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality."